Organisation paid for research Program year 2025 Source: CMS Open Payments

Osf Multi-Specialty Group

Neither a doctor nor a teaching hospital

Research payments

$763,365

361 payments

Through program year 2025, Osf Multi-Specialty Group is reported as receiving $763,365 in research payments, across 361 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $104,220 31
2024 Research $223,668 36
2023 Research $31,528 33
2022 Research $99,379 85
2021 Research $93,459 65
2020 Research $98,687 60
2019 Research $112,424 51

Breakdown

Who paid Research payments · program years 2019–2025
  1. CSL Behring $332,859 149 payments
  2. Janssen Research & Development, LLC $313,563 89 payments
  3. Esperion Therapeutics, Inc. $48,123 84 payments
  4. United Therapeutics Corporation $31,816 9 payments
  5. Abbott Laboratories $18,206 21 payments
  6. AstraZeneca Pharmaceuticals LP $10,061 3 payments
  7. Cook Research Incorporated $5,520 4 payments
  8. Abiomed $3,216 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome $200,551 122 payments
  2. 70033093Afl3002 $87,064 14 payments
  3. A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Large Simple Trial Evaluating the Use of BE1116 (4-Factor Prothrombin Complex Concentrate [Kcentra / Beriplex]) to Improve Survival in Patients With Traumatic Injury and Acute Major Bleeding $74,403 1 payment
  4. A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation $72,783 16 payments
  5. Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II $57,905 26 payments
  6. Prospective Multi Center double blind randomized active controlled triple dummy parallel group sequential adaptive Phase 3 clinical study to compare the efficacy and safety of macitentan and tadalafil monotherapies with the corresponding fixed dose combination in subjects with pulmonary arterial hypertension PAH followed by an open label treatment period with macitentan and tadalafil fixed dose combination therapy $51,393 31 payments
  7. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effects of Bempedoic Acid (Etc-1002) on the Occurrence of Major Cardiovascular Events in Patients With, Or at High Risk For, Cardiovascular Disease Who Are Statin Intolerant $48,123 84 payments
  8. Prospective Multi Center double blind randomized active controlled triple dummy parallel group sequential adaptive Phase 3 clinical study to compare the efficacy and safety of macitentan and tadalafil monotherapies with the corresponding fixed dose combina $35,383 8 payments
  9. A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) $28,221 13 payments
  10. 70033093Acs3003 $26,850 5 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $5,520 4 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record